About EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a publicly listed company based in Watertown (United States) founded in 1987, and was acquired by pSivida in March 2018. Small molecule therapeutics for ophthalmic disorders are developed. The company has 165 employees. EyePoint Pharmaceuticals has completed 2 acquisitions, including Contractordeliverysystems and Icon Bioscience. EyePoint Pharmaceuticals offers products and services including DURAVYUâ„¢ and Durasert Eâ„¢. Its focus areas include Life Sciences, Ophthalmology, Drugs and Retinal Disorders. Its legal entity is PSIVIDA CORP. Its competitors include Rezolute, Aviceda Therapeutics and IVERIC bio; 2 of its 3 listed competitors have raised funding.
Company details
EyePoint Pharmaceuticals was founded in 1987 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics for ophthalmic disorders are developed. A proprietary Durasert technology is employed, consisting of a miniaturized, injectable, sustained-release drug delivery system for small molecules. Lead candidates include Yutiq, targeted at chronic non-infectious uveitis, and EYEP-1901, addressed to wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
- Headquarters Watertown, United States
- Employees 165
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website eyepointpharma.com
- Social LinkedIn X Facebook
- Acquired by pSivida (Mar 2018)
- Legal Name Eyepoint Pharmaceuticals, Inc.
- Annual Revenue$31.37 M (USD)-27.5as on Dec 31, 2025
- Net Profit-$231.96 M (USD)-77.25as on Dec 31, 2025
- EBITDA-$241.13 M (USD)-67.08as on Dec 31, 2025
- Latest Funding Round$15.7M (USD), Post-IPO
Jan 2021
- InvestorspSivida
& 5 more
- Employee Count165
- Investments & AcquisitionsContractordeliverysystems
& 1 more
- Acquired bypSivida
(Mar 2018)
Products & Services of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals offers a comprehensive portfolio of products and services, including DURAVYU™ and Durasert E™.
Investigational treatment for VEGF mediated retinal diseases.
Proprietary system for sustained intraocular drug delivery.
Funding Insights of EyePoint Pharmaceuticals
- Total Rounds 5
- Last Round Post-IPO — $15.7M
- First Round $20M
(Mar 2018)
- Investors Count 5
All 5 funding rounds of EyePoint Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $15.7M | Post-IPO | – | – | |
| Feb 2019 | $60M | Debt – Conventional | – | – | |
| Oct 2018 | $28.9M | Post-IPO | – | – | |
| Mar 2018 | $20M | Debt – Conventional | – | – | |
| Mar 2018 | $9.92M | Post-IPO | – | – |
6 investors in total: 6 institutional.
Investors in EyePoint Pharmaceuticals
EyePoint Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include pSivida, OcuMension and SWK Holdings.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Ophthalmic drugs for eye disorders are developed. | 2017 | ocumension.com | Shanghai, China | |
Provides investment management for life sciences and biotech funds to investors worldwide. | 2006 | rosalindcap.com | Toronto, Canada | |
Investments and advisory services are provided by the holding company. | 2009 | swkhold.com | Dallas, United States | |
Drug delivery systems | 1987 | psivida.com | Watertown, United States |
Investor details for EyePoint Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol EYPT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 2020
- Listed onFRA: PV3B
- Listed entityEyePoint Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS30233G2093
- Share price$3.07 (-7.53% on the day) · 2026-10-13
- Market capitalisation$264.7M
- EPS (diluted, trailing year)$-3.74
- Volume (last session)2,515,785
Financials of EyePoint Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $31.4M | -$232.0M | -$241.1M |
| 2024 | $43.3M | -$130.9M | -$144.3M |
| 2023 | $46.0M | -$70.8M | -$73.2M |
| 2022 | $41.4M | -$102.2M | -$76.5M |
| 2021 | $36.9M | -$58.4M | -$52.5M |
Detailed financial statements for EyePoint Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by EyePoint Pharmaceuticals
EyePoint Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Contractordeliverysystems and Icon Bioscience.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Online pharmacy providing prescription drugs and other health products | iconbioscience.com | Sunnyvale, United States | 2004 | Mar 2018 | •••• | |
Provider of commercial construction services including concrete, painting, and tenant finish | contractordeliverysystems.com | 0 | Oct 2005 | $104M |
Complete acquisition details for EyePoint Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of EyePoint Pharmaceuticals
7 dated milestones of EyePoint Pharmaceuticals across 34 years, from founding to its latest funding, stage changes and deals.
- Founded EyePoint Pharmaceuticals is founded.
- Acquisition Acquires Contractordeliverysystems.
- Funding First funding round of $20.0M.
- Acquisition Acquires Icon Bioscience.
- Exit Acquired by pSivida.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $15.7M.
Competitors of EyePoint Pharmaceuticals
EyePoint Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Rezolute, Aviceda Therapeutics and IVERIC bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rezolutebio.com | 2012 | Denver, United States | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | ||
| avicedarx.com | 2018 | Cambridge, United States | $254.66M | Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas. | ||
| ivericbio.com | 2007 | New York, United States | $206.77M | 94 | Gene therapy solutions for retinal diseases are developed. |
Detailed competitors of EyePoint Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EyePoint Pharmaceuticals
The website of EyePoint Pharmaceuticals (eyepointpharma.com) receives about 3.9K visits a month and ranks #3,819,866 among all websites worldwide, #4,875 in Biotechnology and Pharmaceuticals.
- Monthly visits3.9K
▼ 24.4% vs previous month
- Unique visitors2.2K
per month
- Global rank#3,819,866
among all websites
- Category rank#4,875
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.6
- Average visit9 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with EyePoint Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cocrystalpharma.com | 100% | 2.9K | #6,117,909 | View details | |
empr.com | empr.com | 60% | #153,602 | – |
Top companies in Ophthalmology
3 companies that operate in the same segment as EyePoint Pharmaceuticals (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 24.69 B | 25,941 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eyepoint Pharmaceuticals
Complete news archive for EyePoint Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals was founded in 1987 and raised its 1st funding round 31 years after it was founded.
EyePoint Pharmaceuticals is headquartered in Watertown, United States.
EyePoint Pharmaceuticals has 165 employees.
Annual revenue of EyePoint Pharmaceuticals is $31.37M as on Dec 31, 2025.
EyePoint Pharmaceuticals was founded in 1987 and is headquartered in Watertown, United States. Operations focus on the biotechnology sector, where small molecule-based therapeutics for ophthalmic disorders are developed. A proprietary Durasert technology is employed, consisting of a miniaturized, injectable, sustained-release drug delivery system for small molecules. Lead candidates include Yutiq, targeted at chronic non-infectious uveitis, and EYEP-1901, addressed to wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
EyePoint Pharmaceuticals's top competitors include Rezolute, Aviceda Therapeutics and IVERIC bio.
EyePoint Pharmaceuticals offers DURAVYUâ„¢ and Durasert Eâ„¢.
Yes, EyePoint Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol EYPT.
EyePoint Pharmaceuticals has made 2 acquisitions, including Contractordeliverysystems, and Icon Bioscience.
EyePoint Pharmaceuticals has 6 investors. Key investors include pSivida, OcuMension, SWK Holdings, CRG, and EW Healthcare Partners.
EyePoint Pharmaceuticals operates through Psivida Corp..
Yes. EyePoint Pharmaceuticals was acquired by pSivida in March 2018.

